Research programme: pneumococcal vaccine intranasal - Eurocine Vaccines

Drug Profile

Research programme: pneumococcal vaccine intranasal - Eurocine Vaccines

Latest Information Update: 25 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eurocine
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Pneumococcal infections

Most Recent Events

  • 17 May 2016 Eurocine Vaccines has patent protection for Immunose™ FLU in Russia, Australia and New Zealand
  • 19 Jan 2016 Research programme: pneumococcal vaccine intranasal - Eurocine Vaccines is available for licensing as of 19 Jan 2016. http://www.eurocine-vaccines.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top